Heart Failure

Hormonal Study Shows Valsartan Significantly Reduces Severity Marker

Published in Drug Week, December 14th, 2001

Results of the largest neurohormonal study ever conducted in patients with heart failure demonstrate that the angiotensin II receptor blocker (ARB) valsartan significantly reduces plasma brain natriuretic peptide (BNP), a key biochemical marker of heart failure progression.

The findings were presented in November 2001 at the American Heart Association (AHA) Scientific Sessions by Roberto Latini MD, head of the laboratory of cardiovascular pharmacology, Istituto di Ricerche Farmacologiche, Mario Negri, Milano, Italy. The Valsartan Heart Failure Trial (Val-HeFT) was sponsored by Novartis Pharma AG.

"BNP levels have been shown to correlate with cardiac...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Week

Source: Drug Week (2001-12-14)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry